This week, we dissect a game-changing regulatory shift in Latin America's largest market. Brazil's ANVISA has just proposed a new fast-track approval process for AI-driven medical software, promising to slash market entry timelines for devices already approved by agencies like the FDA. But a closer look reveals a complex new challenge that could catch even the most prepared companies off guard.

Imagine you're a global MedTech company with an FDA-cleared diagnostic AI. You see the 'fast-track' news from Brazil and plan for a quick launch. But your planned submission is suddenly non-compliant, citing a new, demanding annex on data traceability and cybersecurity specific to the Brazilian population that your initial regulatory package never accounted for. This is the hidden reality companies will now face.

What you'll learn in this episode:

- What is ANVISA's new proposed fast-track for AI medical devices?

- Why is the new data governance requirement a hidden barrier for foreign manufacturers?

- How do these proposed Brazilian rules differ from standard FDA or Health Canada requirements?

- Could this 'fast-track' pathway actually delay market entry for unprepared companies?

- What immediate steps should you take to assess your AI's training data for compliance?

- Which specific local data protection protocols (LGPD) are now integrated into regulatory clearance?

- How can this change be leveraged to build a stronger, more defensible market position in Brazil?

Don't let regulatory surprises derail your LATAM expansion. Pure Global offers end-to-end regulatory consulting, combining local expertise with advanced AI tools to streamline market access in Brazil and over 30 other markets. We help you navigate complex changes like ANVISA's new AI rules, ensuring your technical dossier is compliant from day one. Contact us at [email protected] or visit https://pureglobal.com/ to secure your market presence.